XTL Biopharmaceuticals Ltd.(XTLB)Earnings, Financials & Key Ratios
XTLB•NASDAQ
$2.98
Price updated Jul 7, 2026
AboutXTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.Show more
- Revenue$451K
- EBITDA-$2M-158.2%
- Net Income-$1M-57531.9%
- EPS (Diluted)-9.60
- Gross Margin0.67%
- EBITDA Margin-437.47%
- Operating Margin-481.6%
- Net Margin-227.72%
- ROE-26.83%-46727.4%
XTLB Price & Volume
XTL Biopharmaceuticals Ltd. (XTLB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Liquidity Constraints Threaten Clinical Viability
Investment Thesis • Updated 2024Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and insolvency
Key Thesis Takeaways
- XTL Biopharmaceuticals faces an existential threat as its clinical-stage pipeline fails to generate sustainable revenue, leaving the company reliant on sporadic income and potentially dilutive financing.
- The firm's inability to control overhead, evidenced by SG&A expenses of $756,000 in 2024Q3, significantly outpaces its negligible top-line performance.
- Investors should remain cautious as the combination of a $159 million accumulated deficit and minimal cash reserves suggests a high probability of further shareholder dilution or insolvency.
Verdict Logic
the company's precarious liquidity position, characterized by cash reserves of only $371,000 as of 2024Q4, presents an unacceptable risk of imminent capital impairment for shareholders.
XTLB Growth Metrics
XTL Biopharmaceuticals Ltd. (XTLB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM42.37%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM45.45%
Return on Capital
10 Years-31.57%
5 Years-24.59%
3 Years-30.76%
Last Year-50.73%
Peers Comparison
Key metrics vs top competitors for XTL Biopharmaceuticals Ltd. (XTLB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.98 | $327.88K | -0.31 | — | -227.72% | -26.83% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $3.67 | $263.23M | 11.12 | -31.8% | 21.61% | 10.62% | — | |
| $1.16 | $14.85M | -1.29 | 11.8% | -25.66% | -476.72% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $2.71 | $251.14M | -5.02 | — | — | -38.76% | — |
Compare XTLB vs Peers
XTL Biopharmaceuticals Ltd. (XTLB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when XTLB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XTLB Frequently Asked Questions
XTL Biopharmaceuticals Ltd. (XTLB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is XTL Biopharmaceuticals Ltd.'s revenue?
XTL Biopharmaceuticals Ltd. (XTLB) reported $0.5M in revenue for fiscal year 2024.
Is XTLB profitable?
XTL Biopharmaceuticals Ltd. (XTLB) reported a net loss of $1.0M for fiscal year 2024.
Dividend & Returns
What is XTLB's return on equity?
XTL Biopharmaceuticals Ltd. (XTLB) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.
What is XTL Biopharmaceuticals Ltd.'s free cash flow?
XTL Biopharmaceuticals Ltd. (XTLB) had negative free cash flow of $1.7M in fiscal year 2024, likely due to heavy capital investments.